Document is current
Any future updates will be listed below
-
Authors
Andrieu, Charlotte
Stoof, Jojanneke https://orcid.org/0000-0002-8331-1597
AlSultan, Dalal
Ivers, Laura
Berenguer Pina, Jose Javier
Skrobo, Darko
Ballot, Jo
O’Reilly, Debbie
Collins, Denis M.
Eustace, Alex J. https://orcid.org/0000-0002-4092-1360
Quinn, Cecily
Walshe, Janice M.
Gullo, Giuseppe
Walsh, Naomi https://orcid.org/0000-0002-2178-3564
Crown, John
-
Funding
Funding for this research was provided by:
Cancer Clinical Research Trust (CCRT) Ireland
Health Research Board (EIA-2019-013)
- License Information
-
More Information
Article History
Received: 1 October 2025
Revised: 21 November 2025
Accepted: 2 December 2025
First Online: 20 December 2025
Competing interests
: The contribution of Guiseppe Gullo (GG) to this study relates to his previous affiliation at St Vincent’s University Hospital, Dublin, Ireland. GG is currently employed by Replimune Inc.; and owns shares in Replimune Inc and Regeneron Pharmaceuticals. CQ received honoraria from Exact Sciences and Medscape. JC received consulting or advisory fees from MSD Oncology and AstraZeneca; speaker’s bureau fees from Pfizer; honoraria from Pfizer, MSD Oncology, Pierre Fabre and AstraZeneca; research funding from Roche, Puma Biotechnology, Regeneron, Novartis, MSD Oncology and AstraZeneca; travel, accommodations and expenses reimbursements from MSD Oncology, Pfizer, Roche, Daiichi Sankyo Europe GmbH, AstraZeneca and Regeneron; has stock or other ownership of OncoMark Limited and OncoAssure Ltd; and is/was employed by OncoMark Limited and OncoAssure Ltd. DC has received research funding and research materials from Roche/Genentech, WntResearch; research materials from Sanofi, and has received research funding, and consultancy fees from Puma Biotechnology, Inc. All remaining authors have declared no conflicts of interest.
